Comparative Pharmacology
Head-to-head clinical analysis: BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE versus LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE versus LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER.
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE vs LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bupivacaine blocks voltage-gated sodium channels on neuronal membranes, inhibiting the propagation of action potentials and resulting in local anesthesia.
Lidocaine is an amide-type local anesthetic that stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting the initiation and conduction of nerve impulses. It exhibits antiarrhythmic activity by suppressing automaticity and conduction in cardiac tissues.
0.25-0.5% solution, up to 2 mg/kg (max 150 mg) per dose via infiltration, peripheral nerve block, or epidural; may repeat every 3-6 hours as needed. For epidural: 0.5% solution, 15-20 mL for surgical anesthesia.
Antiarrhythmic: 1-1.5 mg/kg IV bolus, may repeat 0.5-0.75 mg/kg in 5-10 minutes; maximum total 3 mg/kg. Followed by continuous IV infusion 1-4 mg/min. Local anesthesia: maximum 4.5 mg/kg (300 mg) without epinephrine; 7 mg/kg (500 mg) with epinephrine.
None Documented
None Documented
Terminal elimination half-life is 2.7 hours (range 1.5-5.5 hours). Prolonged up to 8-10 hours in neonates and 24-48 hours in severe hepatic impairment.
Terminal elimination half-life: 1.5–2 hours (normal cardiac output and hepatic function). Prolonged in heart failure (up to 10 hours), hepatic disease (up to 5–15 hours), and with continuous infusion (due to saturable metabolism).
Renal excretion accounts for approximately 95% of the dose, with about 50% excreted unchanged. The remainder is primarily hepatic metabolism followed by renal elimination of metabolites. Biliary/fecal excretion is minimal (<5%).
Renal: ~90% as metabolites (including monoethylglycinexylidide [MEGX] and glycinexylidide [GX]) and ~10% unchanged. Biliary/fecal: <3%.
Category C
Category A/B
Local Anesthetic
Local Anesthetic / Antiarrhythmic (Class Ib)